Wockhardt Reports ₹78 Crore Q2 Net Profit, Marks Strong Financial Turnaround

Wockhardt, a leading pharmaceutical company, has reported a remarkable turnaround in its financial performance for the second quarter of FY2025–26. Despite a marginal decline in revenue, the company posted a net profit of ₹78 crore, reversing a loss of ₹22 crore recorded in the same quarter last year. Improved operational efficiency and stronger cost management helped drive profitability gains.

Financial Highlights

Revenue and Profitability

Wockhardt’s revenue for Q2 FY2025–26 stood at ₹782 crore, down 3.46% year-on-year. However, the company’s profitability surged sharply, underscoring the effectiveness of its cost optimization initiatives and improved product mix.

The company’s EBITDA rose 39.06% to ₹178 crore, supported by disciplined expense management and stronger performance across key therapeutic segments.

Margin Expansion

A key highlight of the quarter was the significant improvement in EBITDA margin, which expanded by 916 basis points to 22.76%, compared to 13.60% in the prior year. This notable increase reflects enhanced operational efficiency and a focus on higher-margin products.

Profit Turnaround

The most significant development for the quarter was the return to profitability. Wockhardt reported a net profit of ₹78 crore, marking a strong rebound from a ₹22 crore loss in the same quarter last year.

Disclaimer:

This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.

Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.